Impact BioMedical, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Impact BioMedical, INC. (IBO) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $14.01 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-07
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $14.01M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $14.71M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $15.55M.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$8.85M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $14.01M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $14.71M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $15.55M 10-Q · filed 2026-08-07 |
| 2025-09-30 | -$8.85M 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$7.38M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $6.81M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $7.24M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $34.35M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $26.38M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $27.26M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $28.26M 10-K · filed 2026-03-11 |
| 2023-09-30 | $29.58M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $30.70M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $31.82M 10-Q · filed 2024-05-10 |
| 2022-12-31 | $32.67M 10-K · filed 2025-03-28 |
| 2022-09-30 | $36.03M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $38.38M 10-Q · filed 2023-10-05 |
| 2021-12-31 | $39.92M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |